ClinicalTrials.gg
CompletedNCT05946876Updated Sep 25, 2026

A Phase 1 Study of XH-S003 in Healthy Volunteers

A Phase 1 interventional study of XH-S003 (A) and Placebo (B) in Healthy, sponsored by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.. Completed at 1 site in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (part of Fosun Pharma) · Phase 1, Interventional, and Treatment

Updated Sep 25, 2026Sponsor changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
77
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a phase 1, randomised, first-in-human, double-blinded, placebo-controlled, SAD (Single Ascending Dose) and MAD (Multiple Ascending Dose) study to assess the PK, safety, and tolerability of XH-S003 in healthy volunteers. In addition, this study evaluates the effects of food on XH-S003 under a two-period, cross-over study setting.

Read the detailed description

The study is composed of three parts. Part A (SAD portion, 6 cohorts) and Part B (MAD portion, 3 cohorts) of the study will enrol eligible participants and provide various doses of XH-S003 or placebo at a ratio of 3:1 in each cohort. Part C of the study plans to evaluate the food effect on XH-S003.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. is the lead sponsor of 35 studies on the registry; 22 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, aged ≥ 18 to ≤ 55 years old.
  2. between ≥ 19.0 and ≤ 30.0 kg/m2 at Screening, and weight between ≥ 50 kg and ≤ 120.0kg for male, weight ≥ 45 kg and ≤ 120.0kg for female.
  3. Able and willing to comply with the study procedure and the restriction specified in the protocol.
  4. Provision of signed and dated written prior to any study specific procedures.
  5. Female subjects of must have a negative serum pregnancy test result at screening and a negative pregnancy test result at baseline, and agree to use one of the acceptable methods of listed below during the study (from the time of signing the informed consent until one month after the end of study [EOS] or early termination visit evaluation [ET]):

    • The subject's male partner has undergone documented vasectomy with documentation of azoospermia (male sterilization).
    • A documented placement of an intrauterine device (IUD) or intrauterine system (IUS).
    • Consistent use of the same oral contraceptives for at least 3 months before screening, injectable progesterone, subdermal implants, or the use of a barrier method (condom or occlusive cap [diaphragm or cervical/vault caps], which present no effect on IP at the discretion of investigator).
    • Documented tubal ligation (female sterilization).
    • True abstinence: when this is in line with the preferred and usual lifestyle of the subject, including female subjects with same sex partners. Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. Abstinent subjects must agree to use one of the above-mentioned contraceptive methods, if they start sexual relationships during the study.
  6. Male subjects agreeing to use acceptable methods of contraception if the male subject's partner could become pregnant from the time of signing the informed consent until 3 months after EOS/ET. One of the following acceptable methods of contraception must be utilized:

    • Surgical sterilization (vasectomy with documentation of azoospermia).
    • The subject's female partner uses oral contraceptives (including combination estrogen/progesterone pills, progesterone pills), injectable progesterone, or subdermal implants, or a barrier method (condom or occlusive cap [diaphragm or cervical/vault caps]).
    • The subject's female partner uses medically prescribed topically applied transdermal contraceptive patch.
    • The subject's female partner has undergone documented tubal ligation (female sterilization).
    • The subject's female partner has undergone documented placement of an intrauterine device (IUD) or intrauterine system (IUS).
    • True abstinence: when this is in line with the preferred and usual lifestyle of the subject, including male subjects with same sex partners. Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. Abstinent subjects must agree to use one of the above-mentioned contraceptive methods, if they start sexual relationships during the study.
  7. Subjects do not plan to donate sperm or eggs from the time of signing the informed consent until 3 months after EOS/ET.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with a history of allergies to similar ingredients of the study drug or any ingredient in the study drug, or vaccine component; subjects with a history of severe allergic or anaphylactic reactions at the discretion of PI. Subjects with one of the conditions (including, but not limited to):

    • Subjects with history of eczema within 3 years.
    • Subjects with asthma except for resolved childhood asthma.
    • Subjects with clinical syndromes of urticaria at screening or baseline.
  2. Subjects whose abnormalities in past medical history are or other clinical findings suggest the following clinically significant diseases at the discretion of the PI (including but not limited to gastrointestinal, renal, hepatic, neurological, hematologic, endocrine, pulmonary, psychiatric, or cardiovascular and cerebrovascular diseases, which are deemed as clinically significant by PI).
  3. Abnormal liver function tests at screening, defined as (ALT) or aspartate transaminase (AST) > 1.5x (ULN), and >1.5x ULN (isolated bilirubin > 1.5x ULN is acceptable if bilirubin is fractionated and direct bilirubin \< 35%) that are considered by the PI to be clinically significant. Repeat tests are permitted at investigator discretion.
  4. Abnormal findings at Screening or Day -1 (eg, repeated demonstration of a > 450 ms [male] or > 470 ms [female] corrected by Fridericia's formula [QTcF] or Bazett's formula [QTcB]; heart rate [HR] is out of normal range 45-100 bmp; PR is out of normal range 120 -220 msec; QRS is out of normal range \<120msec) that are considered by the PI or designee to be clinically significant. Repeat tests are permitted at investigator discretion.
  5. Subjects with clinically significant infection (e.g., requiring hospitalization or parenteral antimicrobial therapy) within 2 months before screening or active systemic bacterial, viral, or fungal infection or fever with ear temperature > 37.7℃ within 2 weeks before screening at the discretion of the PI.
  6. Known or suspected immunodeficiency, hereditary or acquired complement deficiency.
  7. Clinical laboratory evidence or clinical diagnosis of (HIV) infection, virus (HCV) infection, or chronic virus (HBV) infection (as shown by hepatitis B surface antigen [HBsAg] positivity).
  8. Subjects who had major injuries or underwent major surgery or had not recovered from surgery or had the surgery affecting the drug metabolic process and safety assessment within 6 months prior to screening, or who are scheduled to undergo surgery during the study period.
  9. Donated more than 400 mL of blood within 90 days or donated plasma within 14 days before screening.
  10. Subjects who received blood product transfusion within 90 days before screening.
  11. Used any medications (including but not limited to prescription medication, over-the-counter medication, herb, etc. [except for use]) within 14 days or 7 half-lives (whichever is longer) of administration of the first dose of product.
  12. Subjects positive for drug abuse test or with a history of drug abuse at screening. One repeat test on the same day is permitted.
  13. Subjects with a history of alcohol abuse within 1 month prior to screening (average consuming 14 units or more of alcohol per week: 1 unit = 285 mL of beer, or 25 mL of spirits, or 125 mL of wine) or positive for alcohol breath test (one repeat test on the same day is permitted) at screening.
  14. Subjects who smoked more than 5 cigarettes every day within 1 month prior to screening or who are not willing to quit smoking during the confinement.
  15. Subjects who consume food or beverage containing grapefruit/pomelo or alcohol/caffeine (e.g., coffee, chocolate, cola, tea, etc.) within 48 hours prior to confinement and during the confinement.
  16. Subjects who are unable to avoid strenuous exercise during confinement.
  17. Subjects who have participated in other drug clinical trials within 3 months prior to screening or plan to participate in other clinical trial from enrolment to EOS/ET.
  18. Subjects who are not suitable for venous blood collection.
  19. Any other conditions which, in the opinion of the Investigator, would make the subject unsuitable for enrolment or could interfere with the subject's participation in or completion of the study.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
77 participants (actual)

Study arms

  • Experimental
    A (XH-S003)

    Participants will receive an oral dose of XH-S003 once daily on scheduled day(s). Dosage: Part A : 50mg,100mg, 200mg, 25mg 、600mg 1000mg Part B : 25mg, 50mg, 150mg. Part C : 200 mg

    Drug: XH-S003 (A)

  • Placebo comparator
    B (Placebo)

    Participants will receive oral matching placebo once daily on scheduled day(s)

    Other: Placebo (B)

Interventions

  • DrugXH-S003 (A)

    IP: XH-S003 IP: XH-S003 Dose: 25 mg, 100 mg Dose Formulation: Capsule Route of Administration: Oral

  • OtherPlacebo (B)

    Dose: 25 mg, 100 mg Dose Formulation: Capsule Route of Administration: Oral

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs)

    AEs assessed based on Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

    Time frame: Part A: Upto 10 days

  2. Number of participants with adverse events (AEs)

    AEs assessed based on Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

    Time frame: Part B: Up to 28 days

  3. Number of participants with adverse events (AEs)

    AEs assessed based on Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

    Time frame: Part C: Up to 7 days

  4. Number of participants with clinical laboratory abnormalities

    Time frame: Part A: Upto 10 days

  5. Number of participants with clinical laboratory abnormalities

    Time frame: Part B: Up to 28 days

  6. Number of participants with clinical laboratory abnormalities

    Time frame: Part C: Up to 7 days

07

Study locations

1 site
  • CMAX Clinical Research
    Adelaide, South Australia 5000, Australia
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2023 to primary completion in Jul 2024, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2023
First posted
Jul 14, 2023
StartActual
Aug 24, 2023
Primary completionActual
Jul 11, 2024
CompletionActual
Aug 14, 2024
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sponsor
S-INFINITY Pharmaceuticals Co., Ltd→Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Sponsor S-INFINITY Pharmaceuticals Co., Ltd→Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
    + 3 other changes: identifiers, description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05946876
Responsible party
Sponsor
First posted
Jul 14, 2023
Start date
Aug 24, 2023
Primary completion
Jul 11, 2024
Completion
Aug 14, 2024
Last update
Sep 25, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion